JP2008508885A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508885A5
JP2008508885A5 JP2007525033A JP2007525033A JP2008508885A5 JP 2008508885 A5 JP2008508885 A5 JP 2008508885A5 JP 2007525033 A JP2007525033 A JP 2007525033A JP 2007525033 A JP2007525033 A JP 2007525033A JP 2008508885 A5 JP2008508885 A5 JP 2008508885A5
Authority
JP
Japan
Prior art keywords
antibody
use according
group
antigen
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007525033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/027912 external-priority patent/WO2006135385A2/en
Publication of JP2008508885A publication Critical patent/JP2008508885A/ja
Publication of JP2008508885A5 publication Critical patent/JP2008508885A5/ja
Withdrawn legal-status Critical Current

Links

JP2007525033A 2004-08-05 2005-08-05 インターロイキン−21受容体活性を中和すること Withdrawn JP2008508885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59908604P 2004-08-05 2004-08-05
US63917604P 2004-12-23 2004-12-23
PCT/US2005/027912 WO2006135385A2 (en) 2004-08-05 2005-08-05 Antagonizing interleukin-21 receptor activity

Publications (2)

Publication Number Publication Date
JP2008508885A JP2008508885A (ja) 2008-03-27
JP2008508885A5 true JP2008508885A5 (enExample) 2008-09-04

Family

ID=37309615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525033A Withdrawn JP2008508885A (ja) 2004-08-05 2005-08-05 インターロイキン−21受容体活性を中和すること

Country Status (16)

Country Link
US (2) US20060039902A1 (enExample)
EP (1) EP1773394A2 (enExample)
JP (1) JP2008508885A (enExample)
KR (1) KR20070057789A (enExample)
AR (1) AR051071A1 (enExample)
AU (1) AU2005332996A1 (enExample)
BR (1) BRPI0514138A (enExample)
CA (1) CA2574848A1 (enExample)
CR (1) CR8891A (enExample)
EC (1) ECSP077226A (enExample)
IL (1) IL181044A0 (enExample)
MX (1) MX2007001509A (enExample)
NO (1) NO20070973L (enExample)
RU (1) RU2007102287A (enExample)
TW (1) TW200608995A (enExample)
WO (1) WO2006135385A2 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US20110075507A1 (en) * 1997-10-24 2011-03-31 Revalesio Corporation Diffuser/emulsifier
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
KR20050037552A (ko) 2002-07-15 2005-04-22 와이어쓰 T 헬퍼(th) 세포 발생 및 기능을 조절하는 방법 및조성물
JP4914209B2 (ja) 2003-03-14 2012-04-11 ワイス ヒトil−21受容体に対する抗体および該抗体の使用
MXPA05010035A (es) * 2003-03-21 2005-11-17 Wyeth Corp Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
US7704503B2 (en) 2005-02-14 2010-04-27 Wyeth Llc Use of IL-17F in diagnosis and therapy of airway inflammation
TW200641353A (en) * 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
ATE497975T1 (de) 2005-04-18 2011-02-15 Novo Nordisk As Il-21-varianten
WO2007043641A1 (ja) * 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
BRPI0617664B8 (pt) * 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
KR20080084818A (ko) * 2005-11-25 2008-09-19 각고호우징 게이오기주크 전립선암 치료제
AU2006341398B9 (en) * 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
JP5322653B2 (ja) * 2005-11-28 2013-10-23 ザイモジェネティクス, インコーポレイテッド Il−21アンタゴニスト
AU2007208678B2 (en) * 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
WO2007116962A1 (ja) * 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
WO2008115290A2 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Methods of wound care and treatment
JP5306214B2 (ja) 2006-10-25 2013-10-02 リバルシオ コーポレイション 混合装置
US8609148B2 (en) * 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
JP5595041B2 (ja) 2006-10-25 2014-09-24 リバルシオ コーポレイション 酸素富化溶液を用いる、眼および他のヒト組織の治療処置の方法
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
AU2007336184A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
CN101646459B (zh) * 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
US20100303917A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100029764A1 (en) * 2007-10-25 2010-02-04 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100009008A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US10125359B2 (en) * 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US20100303871A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100303918A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
EP2207669A4 (en) * 2007-10-25 2011-11-02 Revalesio Corp BACTERIOSTATIC OR BACTERIOZIDE COMPOSITIONS AND METHOD
WO2010062628A1 (en) * 2008-10-27 2010-06-03 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100015235A1 (en) * 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
JP5745274B2 (ja) 2007-12-07 2015-07-08 ザイモジェネティクス, インコーポレイテッド 抗ヒトil−21モノクローナル抗体
US20110014624A1 (en) * 2008-03-12 2011-01-20 Wyeth Llc Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
CN102076327B (zh) * 2008-05-01 2014-04-16 利发利希奥公司 治疗消化功能紊乱的组合物和方法
PE20100141A1 (es) 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
AR072136A1 (es) * 2008-05-23 2010-08-11 Wyeth Corp Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
JP5544290B2 (ja) * 2008-06-05 2014-07-09 独立行政法人国立がん研究センター 神経浸潤抑制剤
US20100075329A1 (en) * 2008-09-23 2010-03-25 O'toole Margot Methods for predicting production of activating signals by cross-linked binding proteins
ES2784830T3 (es) 2008-10-08 2020-10-01 Cambridge Entpr Ltd Métodos para el diagnóstico y tratamiento de enfermedad autoinmune como consecuencia de esclerosis múltiple
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
EP2467160B1 (en) * 2009-08-17 2016-11-16 A & G Pharmaceutical, Inc. Materials and methods for the development of an antigen-specific immune non-responsiveness state
KR101004363B1 (ko) * 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 TNF-α와 IL-21 이중 길항제
WO2011119404A1 (en) * 2010-03-26 2011-09-29 Monsanto Technology Llc Portable systems and methods for amplifying nucleotides and detecting nucleotide sequences
SG10201503600XA (en) 2010-05-07 2015-06-29 Revalesio Corp Compositions and methods for enhancing physiological performance and recovery time
HUE060454T2 (hu) 2010-05-28 2023-03-28 Chugai Pharmaceutical Co Ltd Daganatellenes T-sejt-választ fokozó szer
EP2596023A4 (en) * 2010-07-20 2014-03-05 Beth Israel Hospital COMPOSITIONS AND METHODS FOR IL-6 AND IL-21 ANTAGONISTS
BR112013003110A2 (pt) 2010-08-12 2016-06-28 Revalesio Corp composições e métodos para tratamento de taupatia
SI2665486T1 (sl) 2011-01-18 2020-07-31 Bioniz, Llc Sestavki za moduliranje aktivnosti gama-C-citokina
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
KR20130011056A (ko) * 2011-07-20 2013-01-30 주식회사에이앤알쎄라퓨틱스 염증표적 수용체 및 염증 질환 치료용 약물 운반체
EP2565881B1 (en) * 2011-08-30 2018-06-13 ABB Schweiz AG Dry-type transformer
WO2013096732A2 (en) * 2011-12-23 2013-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing viral diseases by blocking interleukin-21
US20160215042A1 (en) * 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
PT3128997T (pt) 2014-04-08 2020-09-04 Boston Pharmaceuticals Inc Moléculas de ligação específicas para il-21 e suas utilizações
WO2016096858A1 (en) * 2014-12-19 2016-06-23 Mabtech Ab Composition, kit and method for inhibition of il-21 mediated activation of human cells
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2018013585A1 (en) * 2016-07-12 2018-01-18 Flagship Pioneering, Inc. Methods and compositions for modulating thymic function
WO2018038898A2 (en) * 2016-08-05 2018-03-01 The Regents Of The University Of California Mithrene and methods of fabrication of mithrene
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CN110124029B (zh) * 2019-04-19 2023-08-11 中山大学附属第六医院 Il-6r抗体及羊水干细胞在制备用于治疗nec的药物中的应用
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
IL302365A (en) * 2020-10-26 2023-06-01 Neptune Biosciences Llc Orthogonal il-21 receptor/cytokine systems
CN119020389A (zh) * 2024-08-26 2024-11-26 江苏省人民医院(南京医科大学第一附属医院) 一种具备il-6r纳米抗体分泌功能的重组枯草芽孢杆菌及其构建方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US425871A (en) * 1890-04-15 Half to james l
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
DE69721548T2 (de) * 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6350892B1 (en) * 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU2001253127A1 (en) * 2000-04-05 2001-10-23 Zymogenetics Inc. Soluble zalpha11 cytokine receptors
EP3254687A1 (en) * 2001-10-04 2017-12-13 Genetics Institute LLC Methods and compositions for modulating interleukin-21 receptor activity
AU2003230834A1 (en) * 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
KR20050037552A (ko) * 2002-07-15 2005-04-22 와이어쓰 T 헬퍼(th) 세포 발생 및 기능을 조절하는 방법 및조성물
JP4914209B2 (ja) * 2003-03-14 2012-04-11 ワイス ヒトil−21受容体に対する抗体および該抗体の使用
MXPA05010035A (es) * 2003-03-21 2005-11-17 Wyeth Corp Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
BRPI0510996A (pt) * 2004-05-19 2007-12-04 Wyeth Corp métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Similar Documents

Publication Publication Date Title
JP2008508885A5 (enExample)
RU2007102287A (ru) Антагонисты активности рецептора интерлейкина-21
CN102307896B (zh) 基于iii型纤连蛋白结构域的支架组合物、方法及用途
JP2014530611A5 (enExample)
JP2020534837A (ja) 活性細胞を含む方法、組成物、及び移植可能な要素
JP2021507690A5 (enExample)
JPWO2020044055A5 (enExample)
JP2004248677A5 (enExample)
CN106188297B (zh) 抗CTLA-4的纳米抗体Nb91及其制备方法与应用
JP2012507994A (ja) Hla−gタンパク質及びその薬学的使用
EP1299522B1 (en) Alteration of cell membrane
CN115028719B (zh) 血清白蛋白结合纳米抗体及其制备方法与应用
CN106046164B (zh) 抗CTLA-4的纳米抗体Nb36及其制备方法与应用
EP2566500B1 (en) Ccl1 for use in therapy
CN120187445A (zh) 用于治疗炎症和自身免疫性疾病的方法和组合物
CN101455846A (zh) 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用
CN104725514A (zh) 新型il23拮抗剂
CN114195889A (zh) 一种SARS-Cov-2-N纳米抗体及其衍生蛋白和应用
CN117866903A (zh) 单域抗体修饰的干细胞及其在疾病治疗中用途
CN118853587A (zh) 一株特异性分泌bp26抗体的单克隆细胞株2d3、单链抗体及制备方法
CN116143926A (zh) 一种抗IL1RAcP的单域抗体及其用途
CN111057154B (zh) 基于驼源Fc片段的免疫原的制备及应用
CN101434656A (zh) Opg-hsp70融合蛋白的制备方法及用途
CN117624360A (zh) 一种抗trem2的单域抗体及其用途
CN113717929A (zh) 含有基因编辑的脂肪干细胞的药物组合物